EMA Redistributes Responsibility For 370 Drugs Currently Overseen By UK
Executive Summary
The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.
You may also be interested in...
‘We’ll Manage,’ Danish Medicines Agency Head’s View On Brexit
He’d rather Brexit weren’t happening, but senior European regulator Thomas Senderovitz says the national medicines agencies across the EU are on track to cope with the expected loss of the UK – a key player – from the EU pharmaceutical regulatory network. There’s no alternative, and they’re putting lots of work into preparing for it, he tells the Pink Sheet.
The Tricky Task Of Bringing Smaller EU Countries Into The Fold
Clusters of excellence, competition as well as co-operation, Brexit, and aiming high. Danish Medicines Agency head Thomas Senderovitz talks national agencies and engagement in an interview with the Pink Sheet.
EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses
The EMA is to further refocus on its core activities to help it deal with “higher than expected” staff losses due to its relocation to Amsterdam.